12 results about "Proinsulin" patented technology

The present application relates to the technical field of mRNA vaccine, and specifically discloses a proinsulin mRNA vaccine for protecting the function and quantity of pancreatic beta cells. The vaccine is composed of a lipid nanoparticle (LNP) and an mRNA wrapped by the LNP; the mRNA is an mRNA sequence encoding proinsulin, and all uridines in the mRNA sequence are replaced by N1-methyl pseudouridine. The mRNA vaccine of the present application realizes the dual protection of the quantity and function of pancreatic beta cells, compared with the existing intervention means which only focus on blood glucose control or immune regulation, the present application delays the occurrence process of type 1 diabetes from the root, and provides a new technical scheme and drug selection for the prevention and early intervention of type 1 diabetes.

The invention relates to a TCEP-based recombinant proinsulin inclusion body denaturation and renaturation method, according to the method, TCEP is added as a reducing agent in the denaturation and renaturation process, compared with the prior art, the yield of proinsulin denaturation and renaturation is increased, and the yield of insulin is remarkably increased. Besides, TCEP is high in reducibility, wide in applicable pH range and extremely low in toxicity, so that the production efficiency and the process stability of the recombinant insulin production process can be remarkably improved, the harm to operators and the environment is reduced, and the requirements of green chemistry and safe production are met.

The application discloses a recombinant protein, a DNA fragment, an expression vector, a preparation method of a transgenic lettuce and an oral hypoglycemic drug, relates to the technical field of biological medicines, and the amino acid sequence of the recombinant protein is shown as SEQ ID NO:1.The recombinant protein, i.e., a human transferrin-proinsulin fusion protein, can utilize the natural combination of the human transferrin-transferrin receptor to mediate the endocytosis transport of proinsulin after being orally taken, pass through the intestinal tract to enter the blood system, and reduce blood sugar.According to animal experiments, the effect of the recombinant protein is close to that of natural insulin, and the recombinant protein realizes oral delivery of insulin.

Systems and methods are provided for providing diabetes patient treatment guidance for a patient in which a biochemical data set is obtained. The biochemical data set comprises test results from a single blood draw of the patient including at least three measurements selected from the set: a high-sensitivity c-reactive protein test, an adiponectin level test, an intact proinsulin level test, an insulin level test, a C-peptide test, a HbA1c test, and an eGFR level test. A demographic data set for the patient is also obtained that comprises the patient's gender and diabetes stage. The biochemical data set and demographic data set is run against one or more rules to determine a first patient therapy pattern. Then, a report is prepared based on an identity of the first therapy patient pattern. The report sets priorities among intervention classes for the patient based on the identity of the first patient pattern.

The invention relates to a fusion protein, a recombinant vector, a host cell and application thereof. According to the fusion protein, a complementary fluorescent molecule is inserted into a proinsulin precursor, the complementary fluorescent molecule is composed of a first fragment and a second fragment, the first fragment is located between a B peptide chain and a C peptide chain of the proinsulin precursor, and the second fragment is connected to the C tail end of an A peptide chain of the proinsulin precursor. The fusion protein can be folded into insulin with fluorescence after being sheared by the signal peptide and the C peptide chain, and can be used for indicating the content of insulin in cells. The recombinant expression vector or the host cell can be used for constructing a cell model. The cell model is used for screening compounds capable of promoting proinsulin maturation and increasing insulin content, and a lead compound is screened by using a high-throughput compound library screening method so as to evaluate the potential therapeutic effect or side effect of the lead compound and serve as a candidate molecule for subsequent drug development and commercialization.

The invention provides a monoclonal antibody for identifying proinsulin. A light chain CDR3 of the monoclonal antibody is shown as SEQ ID NO: 19, a light chain CDR1 of the monoclonal antibody is shown as SEQ ID NO: 20, a light chain CDR2 of the monoclonal antibody is shown as SEQ ID NO: 21, a heavy chain CDR3 of the monoclonal antibody is shown as SEQ ID NO: 22, a heavy chain CDR1 of the monoclonal antibody is shown as SEQ ID NO: 23, and a heavy chain CDR2 of the monoclonal antibody is shown as SEQ ID NO: 24. The monoclonal antibody is used for identifying mouse proinsulin. The monoclonal antibody can specifically recognize the specific epitope of the proinsulin, has the advantages of high recognition specificity, good affinity, high titer and the like, and has wide application value.

The present invention provides a monoclonal antibody that recognizes proinsulin, wherein the amino acid sequence of the light chain CDR3 of the monoclonal antibody is shown in SEQ ID NO: 7, SEQ ID NO: 13, or SEQ ID NO: 19; and the amino acid sequence of the heavy chain CDR3 of the monoclonal antibody is shown in SEQ ID NO: 10, SEQ ID NO: 16, or SEQ ID NO: 22. The monoclonal antibody of the present invention can specifically recognize a specific antigenic epitope of proinsulin, exhibiting advantages such as strong recognition specificity, good affinity, and high potency, and has broad application value.

The invention provides a product for treating type 2 diabetes mellitus based on a stem cell insulin gene vector. The product consists of mesenchymal stem cells modified by genetic engineering and a cell preservation solution, the genetic engineering modified mesenchymal stem cells are obtained by transducing human mesenchymal stem cells by using a recombinant lentiviral vector, and the recombinant lentiviral vector can express a fusion protein composed of three parts of human proinsulin, a linker peptide and a GLP-1 receptor agonist. According to the application, human proinsulin and a GLP-1 receptor agonist are constructed into a single fusion protein, human mesenchymal stem cells are transduced by utilizing a lentiviral vector, and then a standardized three-stage induced differentiation process is carried out, so that a cell therapy product which can intelligently respond to blood glucose changes for a long time and has stable functions is finally obtained. The defects of transient treatment effect, single secretion function and large cell product batch-to-batch difference in the prior art are fundamentally overcome.

The invention provides a monoclonal antibody for identifying proinsulin. A light chain CDR3 of the monoclonal antibody is shown as SEQ ID NO: 13, a light chain CDR1 of the monoclonal antibody is shown as SEQ ID NO: 14, a light chain CDR2 of the monoclonal antibody is shown as SEQ ID NO: 15, a heavy chain CDR3 of the monoclonal antibody is shown as SEQ ID NO: 16, a heavy chain CDR1 of the monoclonal antibody is shown as SEQ ID NO: 17, and a heavy chain CDR2 of the monoclonal antibody is shown as SEQ ID NO: 18. The monoclonal antibody is used for identifying human proinsulin. The monoclonal antibody can specifically recognize the specific epitope of the proinsulin, has the advantages of high recognition specificity, good affinity, high titer and the like, and has wide application value.

The present disclosure is directed to T cell receptors targeting proinsulin and isolated cell populations comprising regulatory T cells exogenously expressing the T cell receptors used to treat Type 1 Diabetes.

Disclosed herein is a peptide that can be used in the therapy or prevention of Type 1 Diabetes (T1D), particularly in a patient with a DR3-DQ2 haplotype, as well as methods of diagnosing or determining treatment efficacy, methods of identifying T1D-relevant antigen drivers, and to methods of identifying subjects as being at high-risk of T1D and patients as being suitable for and / or responsive to T1D treatment.

The current disclosure provides microorganisms, such as lactic acid bacteria (e.g., Lactococcus lactis) containing an exogenous nucleic acid encoding an IL-10 polypeptide and an exogenous nucleic acid encoding a T1D-specific antigen (e.g., a proinsulin) polypeptide, wherein both exogenous nucleic acids are integrated into the bacterial chromosome. Such microbial strains are suitable for human therapy. The disclosure further provides compositions (e.g., pharmaceutical compositions) methods of using the microorganisms and compositions, e.g., for the treatment of type 1 diabetes (T1D), including those with residual beta-cell function, e.g., recent-onset T1D. The microorganism may be administered orally, delivers the microorganism into the gastrointestinal tract, where it is released and expresses the bioactive polypeptides. The methods of the present disclosure are particularly well suited for subjects possessing residual beta-cell function, e.g., for subjects with recent-onset T1D.